Wei Cao1, Xiaosheng Liu1,2,3, Ke Hong4, Zhiyong Ma5, Yuelun Zhang6, Ling Lin1, Yang Han1, Yong Xiong5, Zhengyin Liu1, Lianguo Ruan4, Taisheng Li1,2,3. 1. Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. 2. Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China. 3. Tsinghua-Peking Center for Life Sciences, Beijing, China. 4. Department of Infectious Diseases, Jin Yin-tan Hospital, Wuhan, China. 5. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China. 6. Medial Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Abstract
BACKGROUND: The effective treatment of coronavirus disease 2019 (COVID-19) remains unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in cases of severe COVID-19, but evidence from larger case series is still lacking. METHODS: A multi-center retrospective study was conducted to evaluate the effectiveness of IVIg administered within two weeks of disease onset at a total dose of 2 g/kg body weight, in addition to standard care. The primary endpoint was 28-day mortality. Efficacy of high-dose IVIg was assessed by using the Cox proportional hazards regression model and the Kaplan-Meier curve adjusted by inverse probability of treatment weighting (IPTW) analysis, and IPTW after multiple imputation (MI) analysis. RESULTS: Overall, 26 patients who received high-dose IVIg with standard therapy and 89 patients who received standard therapy only were enrolled in this study. The IVIg group was associated with a lower 28-day mortality rate and less time to normalization of inflammatory markers including IL-6, IL-10, and ferritin compared with the control. The adjusted HR of 28-day mortality in high-dose IVIg group was 0.24 (95% CI 0.06-0.99, p<0.001) in IPTW model, and 0.27 (95% CI 0.10-0.57, p=0.031) in IPTW-MI model. In subgroup analysis, patients with no comorbidities or treated in the first week of disease were associated with more benefit from high-dose IVIg. CONCLUSIONS: High-dose IVIg administered in severe COVID-19 patients within 14 days of onset was linked to reduced 28-day mortality, more prominent with those having no comorbidities or treated at earlier stage.
BACKGROUND: The effective treatment of coronavirus disease 2019 (COVID-19) remains unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in cases of severe COVID-19, but evidence from larger case series is still lacking. METHODS: A multi-center retrospective study was conducted to evaluate the effectiveness of IVIg administered within two weeks of disease onset at a total dose of 2 g/kg body weight, in addition to standard care. The primary endpoint was 28-day mortality. Efficacy of high-dose IVIg was assessed by using the Cox proportional hazards regression model and the Kaplan-Meier curve adjusted by inverse probability of treatment weighting (IPTW) analysis, and IPTW after multiple imputation (MI) analysis. RESULTS: Overall, 26 patients who received high-dose IVIg with standard therapy and 89 patients who received standard therapy only were enrolled in this study. The IVIg group was associated with a lower 28-day mortality rate and less time to normalization of inflammatory markers including IL-6, IL-10, and ferritin compared with the control. The adjusted HR of 28-day mortality in high-dose IVIg group was 0.24 (95% CI 0.06-0.99, p<0.001) in IPTW model, and 0.27 (95% CI 0.10-0.57, p=0.031) in IPTW-MI model. In subgroup analysis, patients with no comorbidities or treated in the first week of disease were associated with more benefit from high-dose IVIg. CONCLUSIONS: High-dose IVIg administered in severe COVID-19 patients within 14 days of onset was linked to reduced 28-day mortality, more prominent with those having no comorbidities or treated at earlier stage.
Authors: Julia Schwaiger; Michael Karbiener; Claudia Aberham; Maria R Farcet; Thomas R Kreil Journal: J Infect Dis Date: 2020-11-13 Impact factor: 5.226
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Tim Rahmel; Felix Kraft; Helge Haberl; Ute Achtzehn; Timo Brandenburger; Holger Neb; Dominik Jarczak; Maximilian Dietrich; Harry Magunia; Frieda Zimmer; Jale Basten; Claudia Landgraf; Thea Koch; Kai Zacharowski; Markus A Weigand; Peter Rosenberger; Roman Ullrich; Patrick Meybohm; Axel Nierhaus; Detlef Kindgen-Milles; Nina Timmesfeld; Michael Adamzik Journal: Crit Care Date: 2022-07-07 Impact factor: 19.334
Authors: Bojana Popovic; Aleksandra Radovanovic Spurnic; Jelena Velickovic; Aleksandra Plavsic; Milica Jecmenica-Lukic; Tijana Glisic; Dusan Ilic; Danka Jeremic; Jelena Vratonjic; Vladimir Samardzic; Zoran Gluvic; Tatjana Adzic-Vukicevic Journal: Front Endocrinol (Lausanne) Date: 2022-06-22 Impact factor: 6.055